Drug Profile
Influenza A virus H1N1 vaccine - CEL-SCI
Alternative Names: L.E.A.P.S. swine flu vaccine - CEL-SCI; LEAPS-H1N1; LEAPS-H1N1-DCLatest Information Update: 18 Jun 2018
Price :
$50
*
At a glance
- Originator CEL-SCI Corporation
- Developer CEL-SCI Corporation; Johns Hopkins University
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 08 Jun 2018 CEL-SCI has patent protection for LEAPS technology in USA
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral)